Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Stifel Reiterates Buy Rating on Intellia Therapeutics (NTLA)

November 7, 2024 10:43 AM EST

Stifel analyst Dae Gon Ha reiterated a Buy rating and $54.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "NTLA has one of the most expansive and diversified pipelines within the CRISPR/Cas gene editing field, and with 3 Ph.3 studies... More